METHYLPREDNISOLONE MYLAN Générique ( DrugBank: Methylprednisolone )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 66 | IgA腎症 | 1 |
66. IgA腎症
臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-004507-31-FR (EUCTR) | 27/01/2017 | 02/02/2017 | N/A | N/A - TIGER | MedDRA version: 19.1;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders | Trade Name: METHYLPREDNISOLONE MYLAN Générique Product Name: METHYLPREDNISOLONE MYLAN Générique INN or Proposed INN: Methylprednisolone Other descriptive name: Methylprednisolone Trade Name: PREDNISONE ARROW 20mg Product Name: PREDNISONE ARROW 20mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: PREDNISONE ARROW 5 mg Product Name: PREDNISONE ARROW 5 mg INN or Proposed INN: Prednisone 5 mg Other descriptive name: Prednisone 5 mg | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 122 | Phase 3 | France |